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Variation in number of general practitioner 
consultations before hospital referral for cancer: 
findings from the 2010 National Cancer Patient 
Experience Survey in England 
Georgios Lyratzopoulos, Richard D Neal, Josephine M Barbiere, Gregory P Rubin, Gary A Abel 
Summary 
Background Information from patient surveys can help to identify patient groups and cancers with the 
greatest potential for improvement in the experience and timeliness of cancer diagnosis. We aimed to 
examine variation in the number of pre-referral consultations with a general practitioner between patients 
with different cancers and sociodemographic characteristics. 
Methods We analysed data from 41 299 patients with 24 different cancers who took part in the 2010 
National Cancer Patient Experience Survey in England. We examined variation in the number of general 
practitioner consultations with cancer symptoms before hospital referral to diagnose cancer. Logistic 
regression was used to identify independent predictors of three or more pre-referral consultations, 
adjusting for cancer type, age, sex, deprivation quintile, and ethnic group. 
Findings We identified wide variation between cancer types in the proportion of patients who had visited 
their general practitioner three or more times before hospital referral (7·4% [625 of 8408] for breast 
cancer and 10·1% [113 of 1124] for melanoma; 41·3% [193 of 467] for pancreatic cancer and 50·6% [939 of 
1854] for multiple myeloma). In multivariable analysis, with patients with rectal cancer as the reference 
group, those with subsequent diagnosis of multiple myeloma (odds ratio [OR] 3·42, 95% CI 3·01–3·90), 
pancreatic cancer (2·35, 1·91–2·88), stomach cancer (1·96, 1·65–2·34), and lung cancer (1·68, 1·48–1·90) 
were more likely to have had three or more pre-referral consultations; conversely patients with 
subsequent diagnosis of breast cancer (0·19; 0·17–0·22), melanoma (0·34, 0·27–0·43), testicular cancer 
(0·47, 0·33–0·67), and endometrial cancer (0·59, 0·49–0·71) were more likely to have been referred to 
hospital after only one or two consultations. The probability of three or more pre-referral consultations 
was greater in young patients (OR for patients aged 16–24 years vs 65–74 years 2·12, 95% CI 1·63–2·75; 
p<0·0001), those from ethnic minorities (OR for Asian vs white 1·73, 1·45–2·08; p<0·0001; OR for black vs 
white 1·83, 1·51–2·23; p<0·0001), and women (OR for women vs men 1·28, 1·21–1·36; p<0·0001). We 
identified strong evidence of interactions between cancer type and age group and sex (p<0·0001 for 
both), and between age and ethnicity (p=0·0013). The model including these interactions showed a 
particularly strong sex effect for bladder cancer (OR for women vs men 2·31, 95% CI 1·98–2·69) and no 
apparent ethnic group differences in young patients aged 16–24 years, whilst the only cancers without an 
apparent age gradient were testicular cancer and mesothelioma. 
Interpretation Our findings could help to prioritise and stratify early diagnosis initiatives and research, 
focusing on patients with cancers and sociodemographic characteristics with the largest potential for 
improvement. 
Funding None. 
Introduction 
Major policy initiatives in several countries aim to reduce the time between symptom onset and diagnosis of cancer 
(often called early diagnosis initiatives).
1
 These initiatives result from the belief that improvements in the timeliness 
of diagnosis will lead to detection of cancer at an earlier disease stage, in turn leading to improved survival.
2
 How-
ever, emerging evidence for determinants of early diagnosis is limited and complex.
3–7
 Greater and faster 
improvements in cancer survival than are currently possible could be achievable if variation in the processes and 
timeliness of cancer diagnosis were better elucidated, helping to focus (and stratify) research and policy initiatives 
where there is the greatest potential for improvement.
8,9
 
Most patients are diagnosed with cancer after having first visited their general practitioner (family doctor) with 
symptoms of the disease.
10
 The number of such visits before hospital referral is a measure of the quality of patient 
experience. Patients express a strong preference for avoiding the inconvenience and stress of reconsulting on 
several occasions with cancer symptoms before diagnostic (and then management) processes are started.
11–13
 In 
view of the well-recognised challenges in defining and measuring time intervals for diagnosis of cancer,
14,15
 analysis 
of variation in the number of pre-referral consultations can usefully complement information that can be derived from 
measuring time intervals. 
The number of pre-referral consultations is easier to define and measure than are time intervals (which can be 
more difficult to define conceptually and, in the context of patient surveys, recall accurately
16
). As a measure, it is 
also relevant to the efficiency of the health-care system and provides a direct link to the diagnostic process and 
interactions occurring during consultation with a general practitioner that can be targeted by subsequent quality 
improvement interventions and research. 
For all these reasons the number of pre-referral primary care consultations of patients with cancer has great 
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potential for use in the context of clinical audit and quality improvement efforts as indicated by a national safety 
review,
14
 and the inclusion of this measure in national audit initiatives
17
 and patient experience surveys. Such 
surveys are increasingly used to help assess the quality of health care alongside clinical outcomes.
18–20
 In 
England, surveys of the experience of patients with cancer were done in 2000, 2004, and 2010, and the UK 
Government has defined patient experience as one of the five domains of health-care quality.
21–23
 
We analysed data from the 2010 National Cancer Patient Experience Survey in England, for the number of 
times patients with cancer had visited their general practitioner for symptoms relating to their cancer before they 
were referred to hospital. We aimed to identify variation in the number of consultations for patients with different 
cancers and sociodemographic characteristics. 
Methods 
Participants and procedures 
We accessed data from the 2010 National Cancer Patient Experience Survey in England through the UK Data 
Archive.
22
 This survey was sent to patients who were treated for cancer in English National Health Service 
(NHS) hospitals during the first quarter of 2010. It was commissioned by the UK Department of Health, and 
undertaken by Quality Health (Chesterfield, UK), a specialised patient survey provider. All survey questions 
were subject to previous cognitive interview testing on samples of patients with different types of cancer in 
different English regions. On the basis of hospital administration records, patients were included in the survey if 
they had International Classification of Diseases (ICD)-10 codes C00 to C99 in the first diagnosis field of their 
care record, excluding C44 (non-melanoma skin cancer). 
Patients were sent the survey by post, with two reminders for non-respondents, excluding patients known to 
have died at the time of invitation. We analysed information on survey question 1, regarding the number of times 
a patient had visited their general practitioner with symptoms caused by their cancer before hospital referral: 
“Before you were told that you needed to go to hospital about cancer, how many times did you see your general 
practitioner about the health problem caused by cancer?” Patients who replied that they had not visited their 
general practitioner with cancer symptoms before diagnosis were excluded from further analysis (this group 
includes patients who first presented with a medical or surgical emergency leading to urgent hospital admission, 
or whose cancer was diagnosed through participation in NHS cancer screening programmes, or incidentally as 
part of an unrelated hospital appointment or admission). Information was therefore analysed from patients who 
responded that they had visited their general practitioner “once”, “twice”, “three or four times”, and “more than five 
times” before they were referred to hospital. 
We defined 24 cancer types based on ICD-10 codes, and restricted further analysis to patients with these cancers. 
These were all cancers included in the 2000 survey (breast, lung, prostate, ovarian, non-Hodgkin lymphoma, colon, 
and rectal cancer—analysed as colorectal by the 2000 survey); and 17 rarer cancers (oesophageal, stomach, 
pancreatic, bladder, renal, endometrial, cervical, laryngeal, melanoma, mesothelioma, thyroid, vulval, testicular, 
brain, Hodgkin’s lymphoma, multiple myeloma, and leukaemia, table 1). Information was available for patients’ age, 
sex, ethnic group, and deprivation score (Index of Multiple Deprivation 2007 score of lower super output area of 
residence). Ethnic group information was based on participants’ responses to survey question 74, using the 2001 
Census Office for National Statistics ethnicity classification. Deprivation quintile groups were defined by applying 
national (England) quintile-defining points (8·257, 13·525, 20·741, and 33·511). Institutional review board or ethics 
approval were not needed. 
Statistical analysis 
Patient experience measures included in the survey are reported publicly and fed back to NHS hospitals and 
multidisciplinary cancer teams using a binary categorisation for more or less positive patient experience.
22
 
According to this categorisation, having visited a general practitioner three or more times with symptoms of 
cancer before hospital referral is regarded as a less positive experience of care compared with having visited a 
general practitioner once or twice. We therefore used this binary categorisation for the purposes of the main 
analysis and sensitivity analysis. STATA version 11.2 was used for all analyses. 
For the main effects analysis, we described the proportion of patients who had visited their general practitioner 
three or more times before hospital referral by cancer type and sociodemographic group, and calculated the 
respective unadjusted odds ratios (ORs). Subsequently, we used multivariable logistic regression models to 
predict the ORs of visiting a general practitioner three or more times before hospital referral, adjusting for cancer 
type and patient characteristics (age, sex, deprivation, and ethnic group). Standard errors were calculated with a 
robust estimator to account for possible non-independence of findings, and significance was tested with joint 
Wald tests for categorical variables. Rectal cancer was used as the reference category for cancer type, because 
it is common in both sexes. By adjusting for sex in this model, the effect size for a specific cancer is interpreted 
as the effect associated with that cancer compared with rectal cancer patients of the same sex. For example, the 
OR for lung cancer compares either a man with lung cancer with a man with rectal cancer, or a woman with lung 
cancer with a woman with rectal cancer. For single sex cancers (eg, testicular) the OR relates to the comparison 
with a patient of the same sex with rectal cancer. 
We examined interactions between each sociodemographic variable and cancer type. We sequentially added to 
the main model described above interaction terms for cancer by age, sex, ethnic group, and deprivation. We also 
investigated an interaction between ethnicity and age, to examine whether the effect associated with being a 
patient from an ethnic minority might differ by age. To maximise power, age and deprivation were treated as 
continuous and ethnicity as a two category (white or non-white) variable for the interaction terms only. We tested 
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significance of interaction effects with a joint Wald test retaining only those terms that were significant. 
Because significant interactions were identified, we used a two-step analytical strategy, first using a simple model 
including main effect variables (age, sex, ethnic group, deprivation, and cancer) without interactions; and 
subsequently using a full model including both main effect and (significant) interaction variables, which was built on 
the simple initial model. The rationale for this approach is that the simple model provides a high level (although 
somewhat inexact) summary of the average variation by patient characteristic and cancer type. This model serves as 
an initial step in understanding the more complex associations examined in more detail by the full model. The findings 
of the simple model should therefore not be interpreted in isolation. Information provided by the two models helps to 
partition overall variation associated with a group of patients into that generated by compositional or contextual factors 
and that which is specific to a disease process (ie, cancer type). For example, the ORs obtained for women by the 
simple model provide information about the average effect of sex on number of pre-referral consultations because of 
compositional (having to do with the patient group itself) or contextual (having to do with the health-care system) 
factors. Whereas the ORs obtained by the full model show how outcomes for women differ from the average sex 
effect for different cancers. 
Ordered logistic regression was considered for all analyses, but not used because of strong evidence that the 
proportional odds assumption was violated (p<0·0001). Therefore, we explored the degree to which associations 
between the outcome and exposure variables differed with different binary cutoff points defining more or less 
positive experience of care by using alternative binary outcome definitions and repeating the main analysis. More 
specifically, binary outcomes focusing on either the least positive experience category (ie, having visited a 
general practitioner more than five times vs any other category) or the most positive experience category (ie, 
having visited a general practitioner once vs any other category) were used. Additionally, we did a series of 
sensitivity analyses comprising stratification of models by sex, restriction of the model to cancers occurring in 
both sexes (and also excluding breast cancer), inclusion of random effects for hospital of treatment or primary 
care organisation (Primary Care Trust), and inclusion of fixed effect variables for NHS region or time since 
treatment initiation (used as a surrogate for recall accuracy). 
We compared the distributions of cancers in survey participants with population-based incidence data for the 24 
cancers. Further, we compared the crude (unadjusted) patterns of variation in number of pre-referral consult-
ations with those reported by the National Audit of Cancer Diagnosis in Primary Care.
17
 This clinical audit project 
collected data for different aspects of the diagnosis of cancer in primary care for 18 879 patients registered with 
14% (1170 of 8387) of all practices in England. It used information from practice records obtained by a family or 
primary health-care professional (eg, practice nurse), and was done between April, 2009, and April, 2010. 
Role of the funding source 
The Cancer Patient Experience Survey 2010 was sponsored by the Department of Health and was undertaken 
by Quality Health. Data were accessed via the UK Data Archive (deposited by the Department of Health). Our 
study is a secondary analysis of these data and as such these organisations had no involvement in study design, 
analysis, and interpretation, nor in the decision to submit the report for publication. The project was not supported 
by any external funding or sponsorship. GL, JMB, and GAA had access to the raw data. GL had full access to all 
of the data and the final responsibility to submit for publication. 
Results 
101 773 patients aged at least 16 years who were treated for their cancer either as inpatients or day cases in 
one of 158 NHS hospital trusts in England were invited to participate. Of those patients, 67 713 (67%) 
completed the survey.
24
 43 792 participants had one of the 24 studied cancers, had visited their general 
practitioner at least once before hospital referral for cancer, and provided a valid response to the question of how 
many times they had visited their general practitioner before hospital referral. Further analysis was restricted to 
the 41 299 (94%) patients who had complete ethnic group and deprivation information (table 2). Of these 
patients, 9671 (23%) reported that they had visited their general practitioner with cancer symptoms three or more 
times before hospital referral. 
In univariable analysis, we identified strong evidence of large variation between different cancers in the 
proportion of patients who had visited their general practitioner three or more times before hospital referral (table 
2). This proportion was lowest for patients with breast cancer and melanoma and highest for patients with 
multiple myeloma and pancreatic cancer (table 2). Multivariable analysis (table 2, figure 1) with rectal cancer as 
the reference category produced concordant findings. The relative ORs for each cancer can be regarded as 
proxy measures of the difficulty of suspecting its diagnosis, adjusted for patient characteristics, with high ORs 
indicating cancers that are hard to diagnose, and low ORs indicating those that might be easier to diagnose. 
However, we caution against a strict interpretation of these results as ranks. The data do not allow us to 
differentiate the difficulty of diagnosing some individual cancer types (eg, laryngeal vs renal cancer) and the 
relative position of cancers should be used as a guide only. 
In univariable analysis, variation by age in the proportion of patients with three or more pre-referral 
consultations was complex. Multivariable analysis, however, showed a simpler relation with strong evidence that 
younger patients had greater odds of having had three or more pre-referral consultations than older patients 
(table 2, figure 2). Stepwise multivariable analysis suggested that the complex univariable age group differences 
were mainly attributable to confounding by cancer type (data not shown). 
Compared with white patients, patients from any other ethnic group were more likely to have visited their 
general practitioner three or more times before hospital referral (table 2, figure 2). Comparing the findings of 
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univariable and multivariable analysis shows that ethnic differences are largely not confounded by cancer type 
or other sociodemographic characteristics. Although in univariable analysis women were less likely than men to 
visit their general practitioner three or more times before hospital referral, the opposite was true in multivariable 
analysis (table 2, figure 2). The discordance between univariable and multivariable findings is mostly attributable 
to confounding effects of sex differences by cancer type (particularly breast cancer). By contrast with what we 
identified for age, ethnic group, and sex, variation between patients in different deprivation quintiles was both 
limited and inconsistent in direction (table 2, figure 2). 
We identified no evidence of interaction between cancer type and either ethnic group or deprivation (p=0·12 
and p=0·076, respectively). However, we noted strong evidence of interactions between cancer type and age 
group and, cancer type and sex, and between ethnic group and age (table 3). In general, for any age group 
comparisons, younger patients were more likely to have  had three or more pre-referral consultations than were 
older patients for any cancer other than testicular and mesothelioma. (figure 3). Similarly, women were more 
likely than men to have had three or more pre-referral consultations for most of the 18 cancers occurring in both 
sexes, except for breast cancer, stomach cancer, and melanoma (figure 4), although none of these latter three 
comparisons were statistically significant. We noted a particularly strong sex effect for bladder cancer (OR for 
women vs men 2·31, 95% CI 1·98–2·69; figure 4). Finally, the interaction between ethnic group and age shows a 
strong pattern of increasing frequency of three or more pre-referral consultations with increasing age of ethnic 
minority patients (figure 5), although we identified no appreciable ethnic differences for patients aged 16–24 
years. 
In view of these interactions, we provide more detailed information on variation by cancer in figure 6, which 
shows the combined effect of cancer and age group, by sex. Because most patients with Hodgkin’s lymphoma 
are young, the typical patient with that cancer has the highest odds of visiting their general practitioner three or 
more times compared with the typical patient with any other cancer. Information included in figure 1 (and table 
2) relating to the simple model (without interactions) should be interpreted in conjunction with information in 
figure 6 and table 3. Further, we profile variation by age group and sex for the 13 most numerous cancer types 
(with >1000 patients in the analysis sample) in the appendix pp 1–7. Interaction model outputs are shown in 
table 3. 
Different binary outcome definitions of the number of general practitioner consultations before hospital referral 
produced much the same findings for either sociodemographic or cancer type patterns (appendix pp 8–9). 
Further sensitivity analyses produced highly concordant findings with those of the main model and interaction 
model (appendix pp 10–22). Specifically, inclusion of a variable for time from initial treatment (used as a 
surrogate for accuracy of patient recall) showed no evidence of confounding by potential recall bias (appendix 
pp 10–11). Restricting the model to patients with cancers occurring in either sex (ie, excluding reproductive 
organ cancers and breast cancer) produced identical ORs for sex and similar ORs for the respective cancers 
(appendix pp 12–15). Stratification of the simple (main effects only) model by cancer produced much the same 
results as expected from the full (interactions inclusive) model with regard to variation between men and 
women by cancer—eg, higher ORs for women with bladder cancer compared with men with bladder cancer 
(appendix pp 16–18). Inclusion of a variable for NHS region showed no confounding by regional variation 
(appendix pp 19–20). Lastly, inclusion of a random effect for either hospital of treatment or primary care 
organisation produced similar findings, showing no evidence for clustering at the respective levels 
(appendix pp 21–22). 
Comparisons with incidence statistics for different cancers showed patterns of over-representation and under-
representation in the study population versus the general population for several cancers (appendix pp 23–24). 
Comparison of our data with those for the number of pre-referral consultations reported by the National Audit of 
Cancer Diagnosis in Primary Care showed concordant patterns of variation by cancer site (Spearman’s rank 
correlation coefficient r=0·899, p<0·0001, figure 7, appendix pp 25–26). 
Discussion 
With data from a national survey of patient experience we identified large variation in the number of times patients 
visit their general practitioner before hospital referral for suspected cancer. Patients with multiple myeloma, 
pancreatic cancer, stomach cancer, lung cancer, Hodgkin’s lymphoma, colon cancer, and ovarian cancer were 
substantially more likely to have visited their general practitioner three or more times before hospital referral than 
were patients with rectal cancer. Younger patients, women, and those belonging to ethnic minority groups were also 
more likely to have had three or more consultations before they were referred to hospital than were older patients, 
men, and white patients, respectively. We identified notable interactions between cancer type and age, cancer type 
and sex, and between age and ethnicity. 
A major strength of the study is its large sample size, which enabled the profiling of several rarer cancers and 
small age or ethnic groups. The survey also has a response rate (67%) that compares favourably with other 
national patient surveys with typical response rates below 40%.
18,20
 The importance of the number of 
consultations with a general practitioner before hospital referral in patients with subsequent diagnosis of cancer 
is increasingly being appreciated.
14,17
 Data for the number of consultations before hospital referral described by 
the National Audit of Diagnosis of Cancer in Primary Care show patterns of variation that are in agreement with 
those recorded with National Cancer Patient Experience Survey data.
17
 These two sources have notably 
different methods of sampling and outcome ascertainment (eg, national vs sub-national coverage of self-
selected practices; and data extraction by a general practitioner or other primary health-care professional based 
 6 
on patient records in the audit project). In view of these substantive differences, this comparison supports the 
validity of the patient-reported data used in our study. 
Direct comparison with previous patient survey data is difficult because earlier national cancer surveys in 
England did not include a question about the number of general practitioner consultations before hospital 
referral and only focused on six cancers. Additionally, previous surveys predated major cancer policy 
developments in the English NHS.
1,25
 Nevertheless, analysis of the national cancer patient survey done in 2000 
identified variation in patient-reported time interval measures between symptom onset and diagnosis in patients 
with different cancers and sociodemographic characteristics.
26,27
 In the same survey, patients with breast 
cancer reported the shortest time from symptom onset to diagnosis, which is in line the findings of our study.
26
 
Relatively short diagnostic intervals for breast cancer have been reported with UK General Practice Research 
Database data.
28
 In the 2000 National Cancer Patient Survey
20
 women, young, and non-white patients reported 
longer intervals between symptom awareness and diagnosis, which likewise agrees with the sociodemographic 
differences we identified. 
The large sample size of the survey allowed for a detailed examination of ethnic group differences—
nevertheless, as is usually the case when exploring ethnic differences in health care, the potential for lack of 
power and heterogeneity within ethnic groups needs to be borne in mind when interpreting the findings. Although 
the frequency of three or more pre-referral consultations was higher in ethnic minority groups than for white 
patients, this was primarily driven by patients in the middle and older age groups. This might indicate particular 
problems about doctor–patient communication with older patients from ethnic minority groups, who might have 
limited health literacy skills and resources. 
Compared with age, sex, and ethnic group differences, those relating to deprivation were small and inconsistent in 
their direction. This finding is reassuring, indicating that in a system with comprehensive coverage such as the NHS 
equal care outcomes can be obtained in patients with different socioeconomic status. However, deprivation 
gradients might have been either overestimated or underestimated because of non-response survey patterns or lack 
of power. Further, our findings might under-estimate the true size of socioeconomic differences in the frequency of 
pre-referral consultations because of measure attributes (ecological index). Less well-educated patients and those 
with limited literacy might have a higher probability of a greater number of pre-referral consultations. Inclusion of a 
question on educational attainment (an individual measure of socioeconomic status) in future surveys will be useful 
to help explore such potential differences, and to help further elucidate the nature and size of socioeconomic 
variation. Examination of time trends in the number of pre-referral consultations was not possible because of the 
cross-sectional nature of the survey. However, repeatable surveys of patients with cancer including such a question 
could support monitoring of this aspect of experience of cancer diagnosis in the future. 
Our study was descriptive and observational, not hypothesis testing. A limitation of the study is that, for 
patients who reported more than one pre-referral consultation, information about the time period during which 
these consultations took place was not available. Also, we could not differentiate between repeat consultations 
because of inability to suspect the diagnosis of cancer, and those that might occur during a short time period to 
follow up clinically appropriate investigations (eg, blood tests). Therefore the number of pre-referral 
consultations is not a perfect surrogate marker of diagnostic quality at the level of an individual patient. 
However, even if part of the recorded variation relates to clinically appropriate management decisions, this 
explanation is unlikely to account for the very large effects noted for groups of patients with different cancers 
and characteristics. 
Another limitation of the study is that we could not take into account variation at the level of general practice 
because this information was not available. Some of the reported differences between patients with different 
cancers or characteristics could be attributable to their concentration in general practices whose patients with 
cancer overall see their doctors more times than average before hospital referral. Research into other aspects of 
patient experience of primary care indicated that for Asian patients, concentration in practices with worse than 
average scores accounts for about half the respective ethnic differences in patient experience.
29
 At least in part, 
however, ethnic differences in the number of pre-referral consultations can indicate differences in the quality of 
patient–doctor communication because of language barriers or sociocultural norms. Research into this issue, 
including qualitative studies, should be a priority to identify how the diagnostic process for patients with cancer 
from ethnic minority groups can be improved (eg, by making translation services more widely available, or by 
developing translated and culturally aware patient information resources—particularly for middle-aged and elderly 
patients). Inclusion of questions about the participants’ native language or English language fluency in future 
surveys could substantiate analysis that will explore this notion, specifically in view of the strong age-gradients in 
ethnic differences. 
We could not examine the correlation between number of pre-referral consultations and time interval measures 
(symptomatic presentation to diagnosis). This issue should be addressed by further research, alongside 
exploration of the potential independent effect of this measure on cancer survival. However, we emphasise the 
value of the number of pre-referral consultations as a measure of both patient experience and auditable quality 
improvement efforts, independent of its association with time interval measures or survival outcomes. 
Although all questions included in the survey were subject to cognitive interview testing,
13
 appreciation of the 
meaning of the question examined in this study might have differed between patients with different characteristics 
(particularly age or ethnicity). Patient survey report questions (eg, whether an event has or has not happened, as 
opposed to whether a patient was or was not satisfied with their care experience) have the least potential for 
sociodemographic differences in appreciation.
30
 Differential understanding of the question is unlikely to account 
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for a major part of the large recorded ethnic differences, or the differences between patients with different 
cancers. 
Consideration of the external validity of our findings is important with regard to potential bias arising from the 
nature of the survey—ie, by design it’s a survey of survivors, excluding patients with short survival.
26,27
 Patients 
with cancers requiring more frequent contact with hospital services (eg, patients with haematological tumours) 
were over-represented in the study sample (appendix pp 23–24). Despite the relatively high (for a patient 
survey) response rate, the proportion of non-responders is likely to vary between patients with different cancers 
and characteristics. In brief, when discussing the external validity of the survey sample we need to consider 
attrition attributable to poor short-term survival, ineligibility for inclusion in the survey (eg, if no active treatment 
or follow-up occurred in an NHS hospital during the recruitment period of the survey), non-response (which 
might be differential between patients of different economic, educational, linguistic competency, and morbidity 
status), and ineligibility for answering the specific survey question (ie, diagnosis of cancer without previous 
symptomatic presentation to a general practitioner). 
Although non-response patterns might imply an increased potential for non-response bias, they do not 
necessarily result in such bias. The presence, size, and direction of non-response bias are notoriously difficult to 
study, but considering the following principles is useful: first, the higher the response rate, the lower the potential 
for non-response bias.
31
 The Cancer Patient Experience Survey 2010 has a response rate (67%) that is 
substantially higher than other large national patient surveys, such as the US HCAPHS survey (response rate 
36%) or the English General Practice Patient Survey (response rate 38%).
18,32
 Second, although non-response 
patterns might bias crude (unadjusted) analysis, after appropriate adjustment for case-mix, the effect of such bias 
(in surveys with an appropriately defined sampling frame) is small.
33,34
 Third, as applicable to all epidemiological 
research, the size of the recorded associations is important. In our study, the relatively high response rate, the 
multivariable analysis used, and the large size of the recorded associations mean that our findings are unlikely to 
result from non-response bias alone. The concordance of crude patterns of variation recorded in the patient 
survey compared with health-care professional ascertained number of pre-referral consultations based on patient 
records also supports the validity of patient-reported data (figure 7, appendix pp 25–26). 
The readiness of general practitioners to suspect cancer diagnosis varies greatly between different cancers. 
We believe that this finding results from differences in the nature and characteristics of symptoms for different 
cancers. Notably, patients with the higher probability of having visited their general practitioner only once or twice 
before hospital referral tend to have cancers that either have known and well-understood cardinal signs and 
symptoms (eg, pigmented lesion in melanoma), or relate to organs that can be easily inspected or palpated (eg, 
breast, testicular, and thyroid cancer). Our findings also provide some indirect evidence of success in achieving 
professional awareness of cancer symptoms and signs for some common cancers, such as breast cancer, 
melanoma, and testicular cancer. 
In general women and younger patients were more likely to have had three or more general practitioner 
consultations before hospital referral, than were men and older patients, respectively. The strength of these 
associations showed little variation with cancer type with a few notable exceptions. Younger patients with 
testicular cancer were more likely to have been referred to hospital after only one or two consultations—possibly 
indicative of keen awareness in general practitioners of the steep age gradients in the incidence of this cancer, 
with a peak in early adulthood. Sex differences in frequency of pre-referral consultations were greatest for 
bladder cancer, which could result from the greater potential for misattribution of bladder cancer symptoms in 
women to benign urinary tract pathology (eg, cystitis) or benign gynaecological presentations. Women with 
bladder cancer are known to have higher probability of more advanced stage at diagnosis,
35
 and substantially 
shorter 1-year relative survival (64% vs 77% in men).
36
 This strong pattern of cancer survival variation by sex is 
unique to bladder cancer. 
Our findings might be particularly applicable to tax-funded health-care systems with a strong primary-care 
gatekeeper function (eg, the NHS) but also have implications for the diagnosis of cancer in community settings in 
general. Most patients with cancer are diagnosed after presenting with symptoms to either generalists or 
specialists working out of hospital (eg, in health-care centres, or private rooms or surgeries). About three-quarters 
of all cancer patients in England are diagnosed after an elective (ie, non-emergency) symptomatic presentation.
10
 
Acknowledging differences in cancer incidence between different patient groups,
37
 we strongly encourage 
research to understand better cancer signs and symptoms in women, young, and ethnic minority patients (panel). 
Our findings can also help to prioritise policy initiatives and further research focused on patients with cancers 
associated with a non-specific symptom signature and greater number of pre-referral consultations (eg, patients 
with pancreatic, stomach, lung, and colon cancers). This problem is complex and requires interventions at 
different levels.
38
 Therefore such research and policy should explore and assess physician-level educational 
interventions, further development of point-of-care decision aids, risk calculators and diagnostic tests, and system 
redesign to enable more appropriate and timely use of specialist diagnostic tests (eg, imaging or endoscopy).
39
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Cancer 
ICD-10 
codes 
ICD-10 code description 
Oesophageal C15 Malignant neoplasm of oesophagus 
Stomach C16 Malignant neoplasm of stomach 
Colon C18 Malignant neoplasm of colon (C18)  
Rectal C19-20 Malignant neoplasm of recto-sigmoid junction (C19), 
and of rectum (C20) 
Pancreatic C25 Malignant neoplasm of pancreas 
Laryngeal C32 Malignant neoplasm of larynx 
Lung C34 Malignant neoplasm of bronchus and lung 
Melanoma C43 Malignant melanoma of skin 
Mesothelioma C45 Mesothelioma 
Breast C50 Malignant neoplasm of breast 
Vulval C51 Malignant neoplasm of vulva 
Cervical C53 Malignant neoplasm of cervix uteri    
Endometrial C54-C55 Malignant neoplasm of corpus uteri (C54), malignant 
neoplasm of uterus, unspecified (C55) 
Ovarian C56 Malignant neoplasm of ovary 
Prostate C61 Malignant neoplasm of prostate 
Testicular C62 Malignant neoplasm of testis 
Renal C64 Malignant neoplasm of kidney, except renal pelvis 
Bladder C67 Malignant neoplasm of bladder 
Brain C71 Malignant neoplasm of brain 
Thyroid C73 Malignant neoplasm of thyroid gland 
Hodgkin’s lympho-
ma 
C81 Hodgkin’s lymphoma 
Non-Hodgkin’s 
Lymphoma (NHL) 
C82, C83, 
C85 
Follicular [nodular] non-Hodgkin's lymphoma (C82), 
diffuse non-Hodgkin's lymphoma (C83), other and 
unspecified types of non-Hodgkin's lymphoma (C85) 
Multiple myeloma C90 Multiple myeloma and malignant plasma cell neo-
plasms 
Leukaemia C91-C95 Lymphoid leukaemia (C91), myeloid leukaemia 
(C92), monocytic leukaemia (C93), other leukaemi-
as of specified cell type (C94), other leukaemias of 
unspecified cell type (C95) 
 
Table 1: International Classification of Diseases (ICD)-10 codes used to define dif-
ferent cancers
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Table 2. Odds ratios and 95% confidence intervals of seeing a general practitioner three or more times before hospital referral, by sex, age, ethnicity, 
deprivation, and cancer type (n=41,299)
 † 
 
 
 
Patients with three or more pre-referral 
consultations 
Crude odds ratios Adjusted odds ratios** 
Patient character-
istics 
N
††
 n % p Odds 
ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval p* 
Odds 
ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval p* 
Men 20,233 5,057 25·0% <0·0001 
Reference  
<0·0001 
Reference  
<0·0001 
Women 21,066 4,614 21·9% 0·84 0·80 0·88 1·28 1·21 1·36 
16-24 282 119 42·2% 
<0·0001 
2·36 1·86 3·00 
<0·0001 
2·12 1·63 2·75 
<0·0001 
25-34 730 208 28·5% 1·29 1·09 1·52 1·82 1·51 2·20 
35-44 2,501 489 19·6% 0·79 0·71 0·88 1·46 1·30 1·65 
45-54 5,532 1,254 22·7% 0·95 0·88 1·02 1·45 1·33 1·57 
55-64 10,352 2,734 26·4% 1·16 1·09 1·23 1·24 1·16 1·32 
65-74 12,702 2,999 23·6% 
 
Reference  Reference  
75-84 7,830 1,624 20·7% 0·85 0·79 0·91 0·87 0·81 0·93 
85+ 1,370 244 17·8% 0·70 0·61 0·81 0·79 0·68 0·91 
White 39,799 9,154 23·0% 
<0·0001 
Reference   
<0·0001 
Reference  
<0·0001 
Mixed 171 64 37·4% 2·00 1·47 2·73 1·81 1.30 2.53 
Asian 635 213 33·5% 1·69 1·43 2·00 1·73 1.45 2.08 
Black 564 200 35·5% 1·84 1·55 2·19 1·83 1.51 2.23 
Chinese 87 27 31·0% 1·51 0·96 2·37 1·32 0.80 2.15 
Other 43 13 30·2% 1·45 0·76 2·78 1·69 0·79 3.62 
Affluent 9,526 2,141 22·5% 
<0·0001 
Reference  
<0·0001 
Reference  
0.0064 
Deprivation group 2 9,480 2,216 23·4% 1·05 0·98 1·13 1·05 0·98 1·13 
Deprivation group 3 8,869 1,985 22·4% 0·99 0·93 1·07 0·98 0·91 1·05 
Deprivation group 4 7,529 1,788 23·7% 1·07 1·00 1·15 1·03 0·95 1·11 
Most deprived 5,895 1,541 26·1% 1·22 1·13 1·32 1·13 1·04 1·22 
Multiple myeloma 1,854 939 50·6% 
 
<0·0001 
3·43 3·02 3·90 
<0·0001 
3·42 3·01 3·90 
<0·0001 
Pancreatic 467 193 41·3% 
 
2·36 1·92 2·89 2·35 1·91 2·88 
Stomach 748 269 36·0% 
 
1·88 1·58 2·24 1·96 1·65 2·34 
Lung 2,362 795 33·7% 
 
1·70 1·50 1·92 1·68 1·48 1·90 
HL 462 195 42·2% 
 
2·44 1·99 3·00 1·67 1·34 2·08 
Colon 3,289 1,044 31·7% 
 
1·56 1·38 1·75 1·58 1·41 1·78 
Ovarian 1,390 504 36·3% 
 
1·90 1·65 2·19 1·56 1·34 1·81 
Brain 218 80 36·7% 
 
1·94 1·45 2·59 1·55 1·16 2·08 
NHL 2,914 937 32·2% 
 
1·59 1·41 1·79 1·50 1·33 1·69 
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Patients with three or more pre-referral 
consultations 
Crude odds ratios Adjusted odds ratios** 
Patient character-
istics 
N
††
 n % p Odds 
ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval p* 
Odds 
ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval p* 
Mesothelioma 275 77 28·0% 
 
1·30 0·98 1·72 1·43 1·08 1·90 
Rectal 2,611 601 23·0% 
 
Reference  Reference  
Renal 564 168 29·8% 
 
1·42 1·16 1·74 1·38 1·12 1·69 
Laryngeal 279 79 28·3% 
 
1·32 1·00 1·74 1·34 1·02 1·77 
Oesophageal 1,099 274 24·9% 
 
1·11 0·94 1·31 1·15 0·98 1·36 
Leukaemia 1,686 465 27·6% 
 
1·27 1·11 1·47 1·15 0·99 1·32 
Prostate 4,059 912 22·5% 
 
0·97 0·86 1·09 1·10 0·98 1·24 
Vulval 171 46 26·9% 
 
1·23 0·87 1·75 1·05 0·74 1·50 
Cervical  287 86 30·0% 
 
1·43 1·09 1·87 0·95 0·72 1·25 
Bladder 5,209 931 17·9% 
 
0·73 0·65 0·82 0·83 0·74 0·93 
Thyroid 399 92 23·1% 
 
1·00 0·78 1·29 0·71 0·55 0·92 
Endometrial 1,149 202 17·6% 
 
0·71 0·60 0·85 0·59 0·49 0·71 
Testicular 275 44 16·0% 
 
0·64 0·46 0·89 0·47 0·33 0·67 
Melanoma 1,124 113 10·1% 
 
0·37 0·30 0·46 0·34 0·27 0·43 
Breast 8,408 625 7·4% 
 
0·27 0·24 0·30 0·19 0·17 0·22 
 
OR=odds ratio. NHL=non-Hodgkin lymphoma.*This model does not allow for effect modification of age and sex by cancer, nor for interaction of age 
by ethnic group, which have been shown to be important. It shows the average effects but should be interpreted in the context of subsequent inter-
action analysis (table 4, figures 3–6). †The analysis sample excludes 673 participants who indicated that they had visited their general practitioner 
before hospital referral at least once in response to question 1, but indicated this not to be the case in response to another survey question (ques-
tion 2, answer category “6”). ‡From joint Wald tests for categorical variables. These tests assess the overall significance of differences across age, 
sex, deprivation, ethnic group and cancer type categories, as applicable (ie, they test the null hypothesis that there is no variation across catego-
ries). §Multivariable analysis, adjusting for cancer type and patient characteristics. By adjusting for sex in this model, the effect size for a given 
cancer is interpreted as the effect associated with that cancer compared to rectal cancer patients of the same sex. For example, the OR for lung 
cancer compares either a man with lung cancer with a man with rectal cancer, or a woman with lung cancer with a woman with rectal cancer. For 
single sex cancers (eg, testicular cancer) the OR relates to the comparison with a rectal cancer patient of the same sex. 
 
Table 2: ORs and 95% CIs of visiting a family doctor three or more times before hospital referral, by sex, age, ethnicity, deprivation, and 
cancer type*
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Table 3. Odds ratios and 95% confidence intervals of seeing a general practitioner three or 
more times before hospital referral obtained from multivariate logistic regression adjusted for 
age, sex, deprivation, ethnicity, cancer type and interactions between cancer type and gender, 
cancer type and age, and ethnicity and age
†
 (n=41,299) 
 
Patient characteristics 
Odds 
ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
p* 
Main Effects     
Men Reference  
0·075 
Women 1·19 0·98 1·43 
16-24 2·93 1·76 4·88 
<0·0001 
 
25-34 2·23 1·53 3·27 
35-44 1·66 1·27 2·17 
45-54 1·49 1·25 1·77 
55-64 1·24 1·12 1·37 
65-74 Reference  
75-84 0·88 0·79 0·98 
85+ 0·80 0·65 1·00 
White Reference  
<0·0001 
 
Mixed 2·23 1·56 3·19 
Asian 2·07 1·69 2·55 
Black 2·06 1·67 2·53 
Chinese 1·59 0·96 2·64 
Other 2·14 0·98 4·65 
Affluent Reference  
0·010 
Deprivation group 2 1·05 0·98 1·13 
Deprivation group 3 0·98 0·91 1·05 
Deprivation group 4 1·02 0·95 1·10 
Most deprived 1·12 1·03 1·21 
Multiple myeloma 3·32 2·79 3·95 
<0·0001 
 
Pancreatic 2·35 1·76 3·13 
Stomach 2·15 1·73 2·67 
Lung 1·62 1·37 1·93 
Hodgkin's lymphoma 1·55 1·03 2·32 
Colon 1·60 1·36 1·87 
Ovary 1·71 1·41 2·09 
Brain 1·28 0·74 2·20 
Non-Hodgkin's lymphoma 1·59 1·35 1·88 
Mesothelioma 1·45 1·05 1·99 
Rectal Reference  
Renal 1·27 0·96 1·69 
Laryngeal 1·17 0·81 1·69 
Oesophageal 1·10 0·89 1·36 
Leukaemia 1·20 0·98 1·46 
Prostate 1·08 0·94 1·25 
Vulvar 1·10 0·75 1·62 
Cervical cancer 0·85 0·52 1·37 
Bladder 0·68 0·59 0·79 
Thyroid 0·87 0·53 1·45 
Endometrial 0·61 0·49 0·77 
Testicular 0·92 0·41 2·05 
Melanoma 0·44 0·32 0·60 
Breast 0·47 0·19 1·12 
Interaction age (continuous) by cancer type (per change in age group) 
1.14 1.05 1.24 
 
1.14 1.05 1.24 
 
Multiple myeloma 0·92 0·82 1·04 
<0·0001 
Pancreatic 0·91 0·75 1·12 
Stomach 0·98 0·84 1·14 
Lung 0·90 0·80 1·01 
Hodgkin's lymphoma 1·04 0·90 1·19 
Colon 0·93 0·84 1·02 
Ovary 1·08 0·95 1·22 
Brain 0·92 0·75 1·14 
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Patient characteristics 
Odds 
ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
p* 
Non-Hodgkin's lymphoma 0·99 0·89 1·09 
Mesothelioma 1·22 0·88 1·69 
Rectal Reference  
Renal 1·07 0·91 1·27 
Laryngeal 0·84 0·62 1·13 
Oesophageal 1·03 0·89 1·20 
Leukaemia 1·13 1·02 1·26 
Prostate 1·08 0·96 1·21 
Vulvar 1·01 0·78 1·31 
Cervical 0·95 0·79 1·16 
Bladder 0·93 0·84 1·04 
Thyroid 1·09 0·93 1·28 
Endometrial 0·97 0·82 1·15 
Testicular 1·30 1·00 1·68 
Melanoma 1·13 0·97 1·32 
Breast 1·13 1·02 1·25 
Interaction gender by cancer type 
Multiple myeloma 1·02 0·79 1·34 
<0·0001 
 
Pancreatic 0·94 0·62 1·43 
Stomach 0·68 0·46 1·00 
Lung 1·00 0·77 1·29 
Hodgkin's lymphoma 1·19 0·78 1·82 
Colon 0·96 0·76 1·23 
Ovary N/A   
Brain 0·98 0·53 1·79 
Non-Hodgkin's lymphoma 0·86 0·68 1·10 
Mesothelioma 1·14 0·56 2·32 
Rectal Reference  
Renal 1·37 0·90 2·08 
Laryngeal 1·17 0·57 2·38 
Oesophageal 1·20 0·84 1·70 
Leukaemia 1·16 0·87 1·55 
Prostate N/A   
Vulvar N/A   
Cervical N/A   
Bladder 1·95 1·53 2·48 
Thyroid 0·94 0·53 1·67 
Endometrial N/A   
Testicular N/A   
Melanoma 0·76 0·50 1·18 
Breast 0·51 0·21 1·24 
Interaction age (continuous) by ethnicity (per change in age group) 
White Reference  
0·0013 
Non-white 1·14 1·05 1·24 
N/A:  Not applicable. 
†
In order to maximise power, age was treated as a continuous variable and 
ethnicity as a two category (White/non-White) variable for the interaction 
terms only. 
*From joint Wald tests for categorical variables. 
 
 
 
 
 
 
 
 15 
 
 
 
0.2
 
0.4
 
0.6
 
 
 
1
2
3
4
5
O
d
d
s
 R
a
ti
o
 M
 m
ye
lo
m
a
 P
a
n
cr
e
a
tic
 S
to
m
a
ch
L
u
n
g
H
L
C
o
lo
n
O
va
ry
B
ra
in
N
H
L
M
e
so
th
e
lio
m
a
R
e
n
a
l
L
a
ry
n
g
e
a
l
O
e
so
p
h
a
g
e
a
l
L
e
u
ka
e
m
ia
P
ro
st
a
te
V
u
lv
a
l
R
e
ct
a
l (
R
e
f.
)
C
e
rv
ic
a
l
B
la
d
d
e
r
T
h
yr
o
id
E
n
d
o
m
e
tr
ia
l
T
e
st
ic
u
la
r
M
e
la
n
o
m
a
B
re
a
st
 
 
 
 
Figure 1: Odds ratios and 95% CIs for three or more general practitioner consultations 
before hospital referral, by cancer type 
The information in this figure is derived from the main effects model (table 2). This model 
does not allow for effect modification of age and sex by cancer, nor for interaction of age by 
ethnic group, which have been shown to be important. It shows the average effects but 
should be interpreted in the context of interaction analysis (table 3, figures 3–6). 
HL=Hodgkin’s lymphoma. NHL=non-Hodgkin lymphoma. Ref=reference.
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Figure 2: Odds ratios and 95% CIs for three or more general practitioner consultations 
before hospital referral, by patient characteristics  
The information in this figure is derived from the main effects model (table 2). This model 
does not allow for effect modification of age and sex by cancer, nor for interaction of age by 
ethnic group, which have been shown to be important. It shows the average effects but 
should be interpreted in the context of interaction analysis (table 3, figures 3–6). 
Ref=reference.
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Figure 3: Effect of age for patients aged 45–54 years vs 65–74 years (reference), by 
cancer type* 
HL=Hodgkin’s lymphoma. NHL=non-Hodgkin lymphoma. For simplicity, information present-
ed in this graph relates to patients from the white ethnic group. *Adjusted odds ratios and 
95% CIs of three or more general practitioner consultations before hospital referral from a 
model including main effects and significant interactions (table 3).
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Figure 4: Effect of sex shown for women vs men (reference), by cancer type* 
HL=Hodgkin’s lymphoma. NHL=non-Hodgkin lymphoma. *Adjusted odds ratios and 95% CIs 
for three or more general practitioner consultations before hospital referral from a model in-
cluding main effects and significant interactions (table 3).
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Figure 5: Effect of ethnic group varying by age (reference white)* 
*The interaction term was modelled for white/non-white categories, so the change of effect 
by age is the same for all minority ethnic groups, but the baseline is different. 
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Figure 6: Variation by cancer, for the combined effect of cancer and age group 
(A) men. (B) women. Each dot represents one of eight age groups (16–24 years, to ≥85 
years). The red dot indicates the modal age group according to population based incidence 
statistics. 95% CIs are only depicted for the modal age group. Some cells (ie, combinations 
of cancer, age group, sex strata) have fewer than five patients: those subgroups are depict-
ed with empty dots. They should be considered an extrapolation of the model and interpret-
ed with caution. HL=Hodgkin’s lymphoma. NHL=non-Hodgkin lymphoma. 
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Figure 7: Comparison of unadjusted proportion of patients with three or more general 
practitioner consultations before hospital referral between the NHS Cancer Patient 
Survey 2010 and the National Audi of Cancer Diagnosis in Primary Care (NACDPC) 
See also appendix pp 25–26. 
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Web appendix 
 
Appendix 1 
Variation by age group and sex (where applicable) for patients with one of the 13 studied cancers 
with the largest sample size (>1,000 patients) 
 
 The following figures are based on the outputs of the ‘full’ (main effects plus significant interactions) 
model – see Table 3 of main paper.   
 
 Data are illustrated for 13 cancers (breast, lung, colon, rectal, prostate, ovarian, endometrial, mela-
noma, oesophageal, bladder, Non-Hodgkin Lymphoma, multiple myeloma and leukaemia) with a 
sample size >1,000 patients. 
 
 Patterns of variation presented in the subsequent figures should be considered in the context of in-
formation presented in Tables 2 and 3 and Figures 1-6 of the main paper.  Effects for ethnic groups 
and deprivation are not displayed because of no evidence of effect modification by cancer type (joint 
test for interaction terms p=0·12 and p=0·076 respectively). 
 
 No effect is plotted for age groups within each cancer with fewer than five cases (including zero 
counts).  
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Melanoma 
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Multiple myeloma 
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Appendix 2 
 Sensitivity analysis using alternative definitions of binary outcome for less / more positive experience regarding the number of general practitioner con-
sultations before hospital referral (n=41,299 for all three models) 
 
This analysis examines the sensitivity of the main analysis model (left) to the definition of the outcome measure. The additional two models repeat the main ef-
fects model but defining the outcome as i) having seen a general practitioner ‘five or more’ times vs. any other category (middle); or ii) having seen a general 
practitioner ‘twice’, ‘three-four’ or ‘five or more’ times vs. ‘once’ (right). Although some odds ratios change substantially depending on definition, the overall 
pattern of variation is consistent across the three models. Ordered logistic regression was considered but not used because of strong evidence that the proportional 
odds assumption was violated (p<0·0001) – see main paper, Methods. 
 
 
Main analysis (odds ratio of having seen GP three 
or more times vs. ‘once’ or ‘twice’) 
Sensitivity analysis focusing on the least positive 
category 
(having seen GP ‘five or more’ times vs. ‘once’, 
‘twice’ or ‘three-four’ times) 
Sensitivity analysis focusing on the most positive 
category 
(having seen GP ‘twice’, ‘three-four’ or ‘five or 
more’ times vs. ‘once’) 
Patient characteristics Odds ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
Odds ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
Odds ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
Men Reference  Reference  Reference  
Women 1·28 1·21 1·36 1·45 1·32 1·58 1·22 1·15 1·28 
16-24 2·12 1·63 2·75 1·79 1·25 2·55 1·71 1·32 2·22 
25-34 1·82 1·51 2·20 1·80 1·37 2·35 1·87 1·58 2·22 
35-44 1·46 1·30 1·65 1·41 1·17 1·69 1·55 1·40 1·72 
45-54 1·45 1·33 1·57 1·44 1·27 1·62 1·35 1·26 1·45 
55-64 1·24 1·16 1·32 1·24 1·13 1·36 1·19 1·13 1·26 
65-74 Reference  Reference  Reference  
75-84 0·87 0·81 0·93 0·78 0·70 0·87 0·92 0·86 0·97 
85+ 0·79 0·68 0·91 0·77 0·60 0·98 0·80 0·71 0·90 
White Reference  Reference  Reference  
Mixed 1·81 1.30 2.53 1·74 1·11 2·73 1·54 1·11 2·14 
Asian 1·73 1.45 2.08 1·76 1·38 2·25 1·56 1·31 1·85 
Black 1·83 1.51 2.23 1·88 1·46 2·42 2·06 1·70 2·49 
Chinese 1·32 0.80 2.15 0·99 0·48 2·06 0·97 0·60 1·55 
Other 1·69 0·79 3.62 2·83 1·18 6·78 1·29 0·63 2·61 
Affluent Reference  Reference  Reference  
Deprivation group 2 1·05 0·98 1·13 1·14 1·02 1·27 1·02 0·96 1·08 
Deprivation group 3 0·98 0·91 1·05 0·97 0·86 1·08 0·97 0·91 1·03 
Deprivation group 4 1·03 0·95 1·11 1·09 0·97 1·23 1·00 0·94 1·07 
Most deprived 1·13 1·04 1·22 1·21 1·07 1·37 1·00 0·93 1·07 
Multiple myeloma 3·42 3·01 3·90 3·91 3·22 4·75 2·90 2·55 3·29 
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Main analysis (odds ratio of having seen GP three 
or more times vs. ‘once’ or ‘twice’) 
Sensitivity analysis focusing on the least positive 
category 
(having seen GP ‘five or more’ times vs. ‘once’, 
‘twice’ or ‘three-four’ times) 
Sensitivity analysis focusing on the most positive 
category 
(having seen GP ‘twice’, ‘three-four’ or ‘five or 
more’ times vs. ‘once’) 
Patient characteristics Odds ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
Odds ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
Odds ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
Pancreatic 2·35 1·91 2·88 2·98 2·23 3·98 2·16 1·76 2·66 
Stomach 1·96 1·65 2·34 2·47 1·90 3·21 1·76 1·49 2·08 
Lung 1·68 1·48 1·90 2·02 1·66 2·47 1·74 1·55 1·95 
Hodgkin's lymphoma 1·67 1·34 2·08 2·43 1·78 3·30 1·79 1·43 2·23 
Colon  1·58 1·41 1·78 1·85 1·53 2·24 1·53 1·38 1·70 
Ovarian 1·56 1·34 1·81 1·75 1·40 2·20 1·32 1·15 1·51 
Brain 1·55 1·16 2·08 2·54 1·74 3·72 1·14 0·86 1·51 
Non-Hodgkin lymphoma 1·50 1·33 1·69 1·65 1·36 2·01 1·36 1·22 1·52 
Mesothelioma 1·43 1·08 1·90 1·16 0·70 1·92 1·76 1·37 2·26 
Rectal Reference  Reference  Reference  
Renal 1·38 1·12 1·69 1·92 1·42 2·59 1·47 1·22 1·77 
Laryngeal 1·34 1·02 1·77 1·36 0·86 2·14 1·46 1·14 1·88 
Oesophageal 1·15 0·98 1·36 1·03 0·77 1·38 1·17 1·02 1·35 
Leukaemia 1·15 0·99 1·32 1·50 1·20 1·88 1·06 0·94 1·20 
Prostate 1·10 0·98 1·24 1·36 1·11 1·67 1·39 1·25 1·54 
Vulval 1·05 0·74 1·50 1·47 0·89 2·45 0·78 0·57 1·06 
Cervical 0·95 0·72 1·25 1·68 1·17 2·43 0·75 0·58 0·96 
Bladder 0·83 0·74 0·93 0·99 0·81 1·21 0·83 0·76 0·92 
Thyroid 0·71 0·55 0·92 0·78 0·51 1·18 0·74 0·60 0·92 
Endometrial 0·59 0·49 0·71 0·68 0·50 0·92 0·56 0·48 0·65 
Testicular 0·47 0·33 0·67 0·35 0·17 0·74 0·60 0·45 0·78 
Melanoma 0·34 0·27 0·43 0·33 0·22 0·50 0·42 0·36 0·49 
Breast 0·19 0·17 0·22 0·22 0·18 0·28 0·19 0·17 0·21 
 
 
               GP:  General Practitioner. 
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Appendix 3 
Sensitivity analysis adjusting for accuracy of patient recall (time since initiation of cancer treatment used as a surrogate marker for ac-
curacy of recall) 
  
This analysis examines whether there is any confounding by possible recall bias in our study. Whilst there is a tendency for patients whose 
treatment started over a year ago to have had higher frequency of the outcome of interest, this does not appear to confound any of the asso-
ciations with cancer type or socio-demographic characteristics. It should be noted that this tendency may reflect recall bias or secular (over 
time) changes in clinical practice and service delivery. 
 
 Main analysis (n=41,299) 
Sensitivity analysis including adjustment for time since treat-
ment initiation 
(n=40,617)** 
Patient characteristics Odds ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
p* Odds ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
p* 
Men Reference  
<0·0001 
Reference  
<0·0001 
Women 1·28 1·21 1·36 1·28 1·21 1·36 
16-24 2·12 1·63 2·75 
<0·0001 
 
2·20 1·69 2·86 
<0·0001 
 
25-34 1·82 1·51 2·20 1·86 1·54 2·25 
35-44 1·46 1·30 1·65 1·48 1·31 1·67 
45-54 1·45 1·33 1·57 1·46 1·35 1·59 
55-64 1·24 1·16 1·32 1·25 1·17 1·33 
65-74 Reference  Reference  
75-84 0·87 0·81 0·93 0·88 0·82 0·94 
85+ 0·79 0·68 0·91 0·81 0·69 0·94 
White Reference  
<0·0001 
 
Reference  
<0·0001 
 
Mixed 1·81 1.30 2.53 1·82 1·29 2·56 
Asian 1·73 1.45 2.08 1·84 1·53 2·21 
Black 1·83 1.51 2.23 1·81 1·48 2·21 
Chinese 1·32 0.80 2.15 1·31 0·80 2·14 
Other 1·69 0·79 3.62 1·51 0·69 3·32 
Affluent Reference  
0·0064 
Reference  
0·0033 
Deprivation group 2 1·05 0·98 1·13 1·05 0·98 1·13 
Deprivation group 3 0·98 0·91 1·05 0·97 0·91 1·05 
Deprivation group 4 1·03 0·95 1·11 1·03 0·95 1·11 
Most deprived 1·13 1·04 1·22 1·14 1·05 1·23 
Multiple myeloma 3·42 3·01 3·90 
<0·0001 
 
3·16 2·77 3·62 
<0·0001 
 
Pancreatic 2·35 1·91 2·88 2·39 1·94 2·94 
Stomach 1·96 1·65 2·34 2·01 1·69 2·41 
Lung 1·68 1·48 1·90 1·70 1·49 1·93 
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 Main analysis (n=41,299) 
Sensitivity analysis including adjustment for time since treat-
ment initiation 
(n=40,617)** 
Patient characteristics Odds ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
p* Odds ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
p* 
Hodgkin's lymphoma 1·67 1·34 2·08 1·64 1·32 2·05 
Colon 1·58 1·41 1·78 1·60 1·42 1·81 
Ovarian 1·56 1·34 1·81 1·52 1·31 1·76 
Brain 1·55 1·16 2·08 1·50 1·12 2·02 
Non-Hodgkin lymphoma 1·50 1·33 1·69 1·46 1·29 1·65 
Mesothelioma 1·43 1·08 1·90 1·45 1·09 1·93 
Rectal Reference  Reference  
Renal 1·38 1·12 1·69 1·35 1·10 1·66 
Laryngeal 1·34 1·02 1·77 1·35 1·03 1·78 
Oesophageal 1·15 0·98 1·36 1·18 1·00 1·40 
Leukaemia 1·15 0·99 1·32 1·07 0·93 1·24 
Prostate 1·10 0·98 1·24 1·09 0·96 1·23 
Vulval 1·05 0·74 1·50 1·08 0·76 1·54 
Cervical 0·95 0·72 1·25 0·96 0·73 1·26 
Bladder 0·83 0·74 0·93 0·79 0·70 0·89 
Thyroid 0·71 0·55 0·92 0·70 0·54 0·91 
Endometrial 0·59 0·49 0·71 0·61 0·51 0·74 
Testicular 0·47 0·33 0·67 0·48 0·34 0·69 
Melanoma 0·34 0·27 0·43 0·35 0·28 0·43 
Breast 0·19 0·17 0·22 0·19 0·16 0·21 
Treatment started 
   < 1 year ago 
Not applicable  
Reference  
<0·0001 
Treatment started between     
1-5 years ago 
1·20 1·13 1·27 
Treatment started 
> 5 years ago 
 
1·20 1·09 1·32 
 
* From joint Wald tests for categorical variables. 
 
** This model uses information from responses to survey question 71 “How long is it since you were first treated for this cancer?” (re-
sponse categories “Less than a year ago”, “1 to 5 years”, “More than 5 years” and “Don’t’ know / Can’t remember”) to define the respec-
tive variable. 
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Appendix 4 
Table Appendix 4-1. Sensitivity analysis by repeating the analysis excluding patients with ‘single gender’ cancers and breast cancer  
 
 
Main analysis – model includes patients with any of 24 can-
cers, including both ‘either gender’ and ‘single gender’ can-
cers 
(n=41,299) 
Sensitivity analysis –model restricted to patients with any of 17 
‘either gender’ cancers (i.e. excluding reproductive organ and 
breast cancer)** 
(n=25,560) 
Patient characteristics 
Odds 
ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
p* Odds ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
P* 
Men Reference  
<0·0001 
Reference  
<0·0001 
Women 1·28 1·21 1·36 1·28 1·21 1·36 
16-24 2·12 1·63 2·75 
<0·0001 
 
2·28 1·72 3·02 
<0·0001 
 
25-34 1·82 1·51 2·20 2·08 1·65 2·62 
35-44 1·46 1·30 1·65 1·80 1·54 2·10 
45-54 1·45 1·33 1·57 1·50 1·35 1·66 
55-64 1·24 1·16 1·32 1·29 1·20 1·39 
65-74 Reference  Reference  
75-84 0·87 0·81 0·93 0·87 0·81 0·95 
85+ 0·79 0·68 0·91 0·78 0·66 0·92 
White Reference  
<0·0001 
 
Reference  
<0·0001 
 
Mixed 1·81 1.30 2.53 1·66 1·11 2·50 
Asian 1·73 1.45 2.08 1·64 1·29 2·08 
Black 1·83 1.51 2.23 1·80 1·37 2·35 
Chinese 1·32 0.80 2.15 1·17 0·66 2·08 
Other 1·69 0·79 3.62 1·60 0·56 4·55 
Affluent Reference  
0·0064 
Reference  
0·029 
Deprivation group 2 1·05 0·98 1·13 1·06 0·97 1·15 
Deprivation group 3 0·98 0·91 1·05 0·98 0·90 1·07 
Deprivation group 4 1·03 0·95 1·11 1·04 0·95 1·13 
Most deprived 1·13 1·04 1·22 1·14 1·03 1·25 
Multiple myeloma 3·42 3·01 3·90 
<0·0001 
 
3·44 3·02 3·92 
<0·0001 
 
Pancreatic 2·35 1·91 2·88 2·35 1·91 2·89 
Stomach 1·96 1·65 2·34 1·97 1·65 2·36 
Lung 1·68 1·48 1·90 1·68 1·48 1·91 
Hodgkin's lymphoma 1·67 1·34 2·08 1·57 1·25 1·96 
Colon 1·58 1·41 1·78 1·59 1·41 1·79 
Ovarian 1·56 1·34 1·81 N/A   
Brain 1·55 1·16 2·08 1·49 1·11 2·00 
Non-Hodgkin lymphoma 1·50 1·33 1·69 1·49 1·32 1·68 
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Main analysis – model includes patients with any of 24 can-
cers, including both ‘either gender’ and ‘single gender’ can-
cers 
(n=41,299) 
Sensitivity analysis –model restricted to patients with any of 17 
‘either gender’ cancers (i.e. excluding reproductive organ and 
breast cancer)** 
(n=25,560) 
Patient characteristics 
Odds 
ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
p* Odds ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
P* 
Mesothelioma 1·43 1·08 1·90 
 
1·44 1·09 1·91 
 
Rectal Reference  Reference  
Renal 1·38 1·12 1·69 1·37 1·11 1·68 
Laryngeal 1·34 1·02 1·77 1·34 1·02 1·77 
Oesophageal 1·15 0·98 1·36 1·16 0·98 1·36 
Leukaemia 1·15 0·99 1·32 1·13 0·97 1·30 
Prostate 1·10 0·98 1·24 N/A   
Vulval 1·05 0·74 1·50 N/A   
Cervical 0·95 0·72 1·25 N/A   
Bladder 0·83 0·74 0·93 0·84 0·75 0·94 
Thyroid 0·71 0·55 0·92 0·67 0·52 0·88 
Endometrial 0·59 0·49 0·71 N/A   
Testicular 0·47 0·33 0·67 N/A   
Melanoma 0·34 0·27 0·43 0·33 0·27 0·42 
Breast 0·19 0·17 0·22 N/A   
 
N/A: Not applicable. 
*From joint Wald tests for categorical variables. 
**I.e. excluding patients with ovarian, endometrial, cervical, vulval, prostate, testicular and breast cancer. 
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Comment on Table Appendix 4-1 
    
This analysis investigates the sensitivity of the main effects model to the inclusion of cancers which occur in either only one sex (ovarian, endometrial, cervi-
cal, vulval, testicular and prostate cancer) or predominantly in one sex (breast cancer). We see little difference between the two models for applicable compari-
sons. In particular it can be seen that: 
 
 The odds ratios (and respective confidence intervals) for gender are identical in either model. 
 The odds ratios for the 17 relevant cancers are very similar in the two models. The minor differences in the odds ratios for 17 relevant cancers princi-
pally reflect variation by chance – because of differences in sample size and composition between the two models – for example the sample size for 
the main model is 41,299 whereas the that of the sensitivity analysis model (after exclusion of patients with the seven relevant cancers) is 25,560.* 
 
 
*Regarding changes in the odds ratios for cancer: We explore the role of chance variation due to sampling differences for the cancer with the largest (alt-
hough still small) difference in odds ratios (OR), which is Hodgkin’s Lymphoma, with OR=1.67 / OR=1.57 in the ‘main analysis’ and in the restricted to 
‘either gender’ cancer model. This cancer has relatively few patients (462) many of whom are young (specifically 37% of all Hodgkin’s Lymphoma pa-
tients are aged 16-34, compared with 2% of patients in the respective age bracket for all other cancers) – see Table Appendix 4-2 below. The difference in 
the odds ratios for Hodgkin’s lymphoma between the two models reflects the large fraction of young patients who have been removed from the analysis 
when restricting to ‘either gender’ cancers [i.e. only 61% of 16-34 year olds included in the main analysis model (n=41,299) are included in the restricted 
model (n=25,560)], thus increasing imprecision. The difference in the age distribution of patients included in either model reflects the fact that ‘single sex’ 
cancers have substantially different age distribution to that of ‘either gender’ cancers – for example the age distribution of testicular and cervical cancer is 
markedly skewed to younger age groups – see below]. These considerations also apply to brain and thyroid cancer – which are the other two cancers with 
the 2
nd
 and 3
rd
 larger differences in odds ratio values (OR=1.55 / OR=1.49 and OR=0.71 / OR 0.67 in the ‘main’ and the ‘restricted’ model respectively). 
I.e., just like Hodgkin’s lymphoma, brain and thyroid cancers also have a small sample size (219 and 399 patients respectively) and an atypically (com-
pared to average) high proportion of young patients – see below). In conclusion differences between the odds ratios by cancer in the two models are only 
minor, and when they occur, they principally reflect differences in the composition and size of the population of patients included in either model. 
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 Table Appendix 4-2. Number and % of patients aged 16-34 by cancer type.   
Italics denote ‘single gender’ cancers and breast cancer 
 
 n N % 
Cancer 16-34 All ages 16-34 
Testicular 108 275 39.3% 
Hodgkin's Lymphoma 170 462 36.8% 
Cervical 54 287 18.8% 
Thyroid 72 399 18.0% 
Brain 35 218 16.1% 
Leukaemia 126 1,686 7.5% 
Melanoma 56 1,124 5.0% 
Non-Hodgkin Lymphoma 81 2,914 2.8% 
Breast 208 8,408 2.5% 
Ovarian 18 1,390 1.3% 
Vulval 2 171 1.2% 
Colon 29 3,289 0.9% 
Endometrial 9 1,149 0.8% 
Rectal 19 2,611 0.7% 
Renal 3 564 0.5% 
Lung 11 2,362 0.5% 
Stomach 2 748 0.3% 
Multiple myeloma 3 1,854 0.2% 
Bladder 5 5,209 0.1% 
Oesophageal 1 1,099 0.1% 
Laryngeal 0 279 0.0% 
Mesothelioma 0 275 0.0% 
Prostate 0 4,059 0.0% 
Pancreatic 0 467 0.0% 
All cancers 1,012 41,299 2.5% 
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Appendix 5 
Table Appendix 5-1. Sensitivity analysis with regression models stratified to either sex 
 
 Model restricted to men (n=20,233) Model restricted to women (n=21,066) 
Patient characteristics 
Odds rati-
os 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
p* Odds ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
p* 
16-24 1·80 1·23 2·62 
<0·0001 
 
2·60 1·79 3·78 
<0·0001 
 
25-34 2·03 1·49 2·77 1·73 1·36 2·20 
35-44 1·63 1·33 2·01 1·39 1·19 1·62 
45-54 1·42 1·25 1·61 1·46 1·30 1·64 
55-64 1·24 1·14 1·34 1·25 1·13 1·37 
65-74 Reference  Reference  
75-84 0·90 0·82 0·99 0·83 0·74 0·93 
85+ 0·80 0·65 0·99 0·74 0·59 0·93 
White Reference  
<0·0001 
 
Reference  
<0·0001 
 
Mixed 1·76 1·07 2·92 1·86 1·18 2·91 
Asian 1·64 1·26 2·13 1·84 1·43 2·37 
Black 2·40 1·84 3·13 1·37 1·03 1·84 
Chinese 1·32 0·62 2·79 1·35 0·70 2·60 
Other 2·23 0·53 9·32 1·60 0·65 3·91 
Affluent Reference  
0·15 
Reference  
0·055 
Deprivation group 2 1·08 0·98 1·19 1·02 0·92 1·13 
Deprivation group 3 1·01 0·92 1·12 0·93 0·84 1·04 
Deprivation group 4 1·02 0·92 1·13 1·03 0·92 1·15 
Most deprived 1·13 1·01 1·26 1·12 0·99 1·25 
Multiple myeloma 3·40 2·87 4·02 
<0·0001 
 
3·50 2·85 4·29 
<0·0001 
 
Pancreatic 2·44 1·86 3·20 2·27 1·66 3·11 
Stomach 2·16 1·75 2·66 1·49 1·07 2·06 
Lung 1·67 1·41 1·97 1·70 1·40 2.06 
Hodgkin's lymphoma 1·55 1·14 2·10 1·80 1·31 2·49 
Colon 1·61 1·38 1·88 1·58 1·32 1·90 
Ovarian N/A   1·63 1·35 1·96 
Brain 1·57 1·07 2·30 1·51 0·96 2·40 
Non-Hodgkin lymphoma 1·62 1·38 1·90 1·39 1·15 1·67 
Mesothelioma 1·39 1·01 1·91 1·51 0·79 2·88 
Rectal Reference  Reference  
Renal 1·22 0·93 1·58 1·67 1·21 2·32 
Laryngeal 1·31 0·96 1·78 1·44 0·78 2·68 
Oesophageal 1·09 0·89 1·33 1.29 0.97 1·73 
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 Model restricted to men (n=20,233) Model restricted to women (n=21,066) 
Patient characteristics 
Odds rati-
os 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
p* Odds ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
p* 
Leukaemia 1·09 0·90 1·32 1.22 0.98 1·53 
Prostate 1·07 0·93 1·23 N/A   
Vulval N/A   1.11 0.76 1·60 
Cervical N/A   1.00 0.74 1·35 
Bladder 0·68 0·58 0·78 1.33 1.09 1·61 
Thyroid 0·78 0·48 1·26 0.72 0.52 0·98 
Endometrial N/A   0.62 0.50 0·77 
Testicular 0·45 0·31 0·65 N/A   
Melanoma 0·40 0·30 0·55 0.30 0.22 0·41 
Breast 0·42 0·17 1·02 0.20 0.17 0·24 
 
N/A: Not applicable. 
*From joint Wald tests for categorical variables. 
 
Comment on Table Appendix 5-1 
 
This analysis examines the effect of stratifying the main effects analysis by gender. It can be seen that: 
 
 Subject to sampling differences, patterns of variation by socio-demographic characteristic (other than gender) are similar in either 
model (i.e. for patients of either sex). 
 
 Patterns of gender variation by cancer fall into two patterns. For some cancers the odds ratios are similar for both men and women 
(e.g. multiple myeloma, brain and thyroid cancer). For other cancers, the odds ratios differ substantially for patients of either sex 
(e.g. bladder, renal, stomach cancer) – as could be expected given the interaction effects by sex observed for these cancers (see also 
main text, Table 3, Figure 4, and also Figures 6A-B).  We also provide a graphical summary of data on gender variation by cancer 
presented in the above table below (Figure Appendix 5-1). 
 
When considering differences in odds ratio by cancer between men and women, we recommend use of data from the ‘full’ model (inclusive of 
both main effect and interaction variables, Table 3, and Figures 3-6) because using ‘stratified’ models can lead to misinterpretation (e.g. by po-
tentially comparing non-significant effects in men with significant ones in women and vice versa), reduces power, increases imprecision and 
does not allow for quantification or testing of the significance of the effect associated with sex. 
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Figure Appendix 5-1. Adjusted odds ratios and 95% confidence intervals of three or more general practitioner consultations before  
hospital referral, for cancer type from main effects models stratified by gender (please see notes on Table Appendix 5-1 for interpretation). Men are denoted in red and 
women in blue dots 
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M. myeloma: Multiple myeloma; HL: Hodgkin’s lymphoma; NHL: Non-Hodgkin lymphoma. 
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Appendix 6 
Sensitivity analysis for region (including in the analysis model a fixed effect variable for NHS Region) 
 
This analysis investigates the degree of any regional variation in the probability of seeing a general practitioner three or more times be-
fore hospital referral for cancer; and whether it has any confounding effect. Whilst there is some weak evidence of regional variation 
(p=0·021) there is no indication of confounding. 
 
 Main analysis (n=41,299) 
Sensitivity analysis including adjustment for NHS region 
(n=41,051) 
Patient characteristics 
Odds 
ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
p* Odds ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
p* 
Men Reference  
<0·0001 
Reference  
<0·0001 
Women 1·28 1·21 1·36 1·28 1·21 1·36 
16-24 2·12 1·63 2·75 
<0·0001 
 
2·11 1·63 2·74 
<0·0001 
 
25-34 1·82 1·51 2·20 1·83 1·51 2·21 
35-44 1·46 1·30 1·65 1·47 1·30 1·66 
45-54 1·45 1·33 1·57 1·45 1·33 1·58 
55-64 1·24 1·16 1·32 1·24 1·16 1·32 
65-74 Reference  Reference  
75-84 0·87 0·81 0·93 0·86 0·81 0·93 
85+ 0·79 0·68 0·91 0·78 0·67 0·91 
White Reference  
<0·0001 
 
Reference  
<0·0001 
 
Mixed 1·81 1.30 2.53 1·78 1·28 2·49 
Asian 1·73 1.45 2.08 1·70 1·41 2·04 
Black 1·83 1.51 2.23 1·76 1·44 2·14 
Chinese 1·32 0.80 2.15 1·29 0·79 2·12 
Other 1·69 0·79 3.62 1·63 0·76 3·49 
Affluent Reference  
0·0064 
Reference  
0·0015 
Deprivation group 2 1·05 0·98 1·13 1·06 0·99 1·14 
Deprivation group 3 0·98 0·91 1·05 0.99 0·92 1·06 
Deprivation group 4 1·03 0·95 1·11 1·04 0·96 1·12 
Most deprived 1·13 1·04 1·22 1·16 1·07 1·26 
Multiple myeloma 3·42 3·01 3·90 
<0·0001 
 
3·42 3·00 3·89 
<0·0001 
 
Pancreatic 2·35 1·91 2·88 2·32 1·89 2·86 
Stomach 1·96 1·65 2·34 1·97 1·65 2·35 
Lung 1·68 1·48 1·90 1·67 1·48 1·90 
Hodgkin's lymphoma 1·67 1·34 2·08 1·66 1·33 2·07 
Colon 1·58 1·41 1·78 1·59 1·41 1·79 
Ovarian 1·56 1·34 1·81 1·55 1·33 1·79 
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 Main analysis (n=41,299) 
Sensitivity analysis including adjustment for NHS region 
(n=41,051) 
Patient characteristics 
Odds 
ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
p* Odds ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
p* 
Brain 1·55 1·16 2·08 1·55 1·16 2·08 
Non-Hodgkin lymphoma 1·50 1·33 1·69 1·49 1·32 1·68 
Mesothelioma 1·43 1·08 1·90 
 
1·44 1·08 1·90 
 
Rectal Reference  Reference  
Renal 1·38 1·12 1·69 1·38 1·13 1·69 
Laryngeal 1·34 1·02 1·77 1·36 1·03 1·80 
Oesophageal 1·15 0·98 1·36 1·16 0·98 1·36 
Leukaemia 1·15 0·99 1·32 1·13 0·98 1·31 
Prostate 1·10 0·98 1·24 1·10 0·98 1·24 
Vulval 1·05 0·74 1·50 1·05 0·74 1·50 
Cervical 0·95 0·72 1·25 0·95 0·72 1·25 
Bladder 0·83 0·74 0·93 0·83 0·74 0·93 
Thyroid 0·71 0·55 0·92 0·72 0·56 0·93 
Endometrial 0·59 0·49 0·71 0·59 0·49 0·70 
Testicular 0·47 0·33 0·67 0·47 0·33 0·67 
Melanoma 0·34 0·27 0·43 0·34 0·28 0·43 
Breast 0·19 0·17 0·22 0·19 0·17 0·22 
West Midlands  
Not applicable  
Reference  
0·021 
East Midlands  0·96 0·86 1·06 
East of England 1·05 0·95 1·16 
London 1·00 0·91 1·11 
North-East 0·86 0·76 0·97 
North--West 0·92 0·83 1·02 
South-Central 1·02 0·91 1·15 
South-East 0·92 0·82 1·04 
South-West 0·95 0·87 1·05 
Yorkshire and Humber 0·91 0·82 1·00 
 
NHS: National Health Service. 
 
*From joint Wald tests for categorical variables. 
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Appendix 7 
Sensitivity analysis by inclusion of random effect for hospital of treatment, and primary care organisation  
(n=41,299 for all three models) 
 
With this analysis we investigate whether there is any evidence that any of the socio-demographic or cancer differences are caused by clustering of groups of patients 
within either certain hospitals or primary care organisations. Ideally we would use general practice as a random effect but such data were not available (see also main 
paper). Whilst there is some evidence of variation by hospital or primary care organisation (p=0·0020 for hospital random effect, and p= 0·051 for primary care or-
ganisation random effect, respectively) there is very little change in the odds ratios of the main effect variables. Furthermore the confidence intervals also change very 
little. These observations indicate that none of the observed associations with cancer type or socio-demographic characteristic are caused by clustering at the level of 
hospital or primary care organisation.  
 
 
Main analysis (no random effect variable includ-
ed) 
Model including a random effect for hospital of 
treatment* 
Model including a random effect for primary care 
organisation**  
Patient characteristics Odds ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval Odds ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval Odds ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
Men Reference  Reference  Reference  
Women 1·28 1·21 1·36 1·28 1·21 1·36 1·28 1·21 1·36 
16-24 2·12 1·63 2·75 2·09 1·61 2·73 2·12 1·63 2·75 
25-34 1·82 1·51 2·20 1·82 1·51 2·19 1·82 1·51 2·20 
35-44 1·46 1·30 1·65 1·46 1·29 1·64 1·46 1·30 1·65 
45-54 1·45 1·33 1·57 1·44 1·33 1·57 1·45 1·33 1·57 
55-64 1·24 1·16 1·32 1·24 1·16 1·32 1·24 1·16 1·32 
65-74 Reference  Reference  Reference  
75-84 0·87 0·81 0·93 0·87 0·81 0·93 0·87 0·81 0·93 
85+ 0·79 0·68 0·91 0·79 0·68 0·91 0·79 0·68 0·91 
White Reference  Reference  Reference  
Mixed 1·81 1.30 2.53 1·80 1·29 2·52 1·81 1·30 2·53 
Asian 1·73 1.45 2.08 1·73 1·44 2·07 1·73 1·45 2·07 
Black 1·83 1.51 2.23 1·81 1·49 2·19 1·83 1·51 2·22 
Chinese 1·32 0.80 2.15 1·31 0·81 2·13 1·31 0·81 2·13 
Other 1·69 0·79 3.62 1·66 0·81 3·41 1·68 0·82 3·44 
Affluent Reference  Reference  Reference  
Deprivation group 2 1·05 0·98 1·13 1·06 0·99 1·14 1·05 0·98 1·13 
Deprivation group 3 0·98 0·91 1·05 0·98 0·91 1·06 0·98 0·91 1·05 
Deprivation group 4 1·03 0·95 1·11 1·03 0·96 1·12 1·03 0·95 1·11 
Most deprived 1·13 1·04 1·22 1·14 1·05 1·23 1·13 1·04 1·23 
Multiple myeloma 3·42 3·01 3·90 3·43 3·01 3·91 3·43 3·01 3·91 
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Main analysis (no random effect variable includ-
ed) 
Model including a random effect for hospital of 
treatment* 
Model including a random effect for primary care 
organisation**  
Patient characteristics Odds ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval Odds ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval Odds ratios 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
Pancreatic 2·35 1·91 2·88 2·34 1·90 2·88 2·35 1·91 2·89 
Stomach 1·96 1·65 2·34 1·96 1·64 2·34 1·97 1·65 2·35 
Lung 1·68 1·48 1·90 1·68 1·48 1·91 1·68 1·48 1·90 
Hodgkin's lymphoma 1·67 1·34 2·08 1·67 1·34 2·08 1·67 1·34 2·08 
Colon  1·58 1·41 1·78 1·58 1·41 1·78 1·58 1·41 1·78 
Ovarian 1·56 1·34 1·81 1·55 1·34 1·80 1·56 1·34 1·81 
Brain 1·55 1·16 2·08 1·57 1·16 2·10 1·56 1·16 2·09 
Non-Hodgkin lymphoma 1·50 1·33 1·69 1·50 1·33 1·69 1·50 1·33 1·69 
Mesothelioma 1·43 1·08 1·90 1·43 1·08 1·89 1·43 1·08 1·90 
Rectal Reference  Reference  Reference  
Renal 1·38 1·12 1·69 1·38 1·12 1·69 1·38 1·12 1·69 
Laryngeal 1·34 1·02 1·77 1·36 1·03 1·79 1·35 1·02 1·79 
Oesophageal 1·15 0·98 1·36 1·16 0·98 1·36 1·16 0·98 1·37 
Leukaemia 1·15 0·99 1·32 1·14 0·99 1·32 1·15 0·99 1·32 
Prostate 1·10 0·98 1·24 1·11 0·98 1·25 1·11 0·98 1·25 
Vulval 1·05 0·74 1·50 1·04 0·73 1·49 1·05 0·74 1·50 
Cervical 0·95 0·72 1·25 0·94 0·71 1·24 0·95 0·72 1·25 
Bladder 0·83 0·74 0·93 0·83 0·74 0·93 0·83 0·74 0·93 
Thyroid 0·71 0·55 0·92 0·71 0·55 0·92 0·71 0·55 0·92 
Endometrial 0·59 0·49 0·71 0·59 0·49 0·71 0·59 0·49 0·71 
Testicular 0·47 0·33 0·67 0·47 0·33 0·67 0·47 0·33 0·67 
Melanoma 0·34 0·27 0·43 0·34 0·28 0·43 0·34 0·28 0·42 
Breast 0·19 0·17 0·22 0·19 0·17 0·22 0·19 0·17 0·22 
 
NHS: National Health Service 
*NHS Trust 
**NHS Primary Care Trust 
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Appendix 8 
Patterns of distribution of cancers compared with population incidence statistics 
 
 
We compared the distribution of cancers in the 67,713 survey respondents and in the 41,299 patients included in the analysis 
against population-based incidence statistics.
1
 Because patterns were very similar for all survey respondents and for patients 
in the analysis sample,
2
 we only report comparisons between population statistics and survey respondents (n=67,713) hereaf-
ter. It was felt appropriate to also consider 1-year relative survival.
3
 We hypothesised that cancers with low short-term sur-
vival may be under-represented in the survey sample, and vice versa.  
 
An inconsistent pattern of comparisons is apparent, including cancers that are under-represented, cancers that are over-
represented, and cancers that appear to be appropriately represented in the survey sample (Figures A-B, below).  
 
Two cancers with very low 1-year survival (i.e. pancreatic and lung cancer) were substantially under-represented. However, 
some cancers with very high 1-year survival (such as prostate cancer in men, and melanoma in both sexes) were also under-
represented, possibly reflecting non-response patterns specific to those cancers or confounding by age non-response patterns.  
 
Breast cancer and cancers requiring frequent contact with hospital services (e.g. bladder and haematological cancers) were al-
so over-represented.  
 
A number of cancers (including cancers with both low and average survival) appear to be neither over- nor under-represented 
(oesophageal, stomach and colon cancers). 
 
We urge caution about the potential misinterpretation of these findings: The patterns are crude (unadjusted) and some of the 
apparent variation may be explained by non-response patterns by age, deprivation or ethnicity. Time from diagnosis and 
treatment initiation may also be relevant (the survey was dominated by patients whose treatment started in the last year). 
Lastly, it is also important to consider the pattern of hospital care (treatment or follow-up appointments) for different cancers. 
For example patients with bladder and haematological cancers tend to have a larger number of outpatient / day-case appoint-
ments or treatment sessions compared to the average cancer patient. The exact direction and size of these sources of variation 
is complex and difficult to infer.  
 
We also urge caution against the potential over-interpretation of these patterns as indicative of ‘non-response bias’: we ex-
plain in the Discussion section of the main paper why non-response patterns are far from being a sufficient condition for non-
response bias. Given the relatively high response rate, the multivariable (case-mix adjusted) analysis used, and the large size 
of observed associations, it is unlikely that the findings can simply reflect non-response bias. 
 
 
 
 
 
 
                                                 
1
 Office for National Statistics, Cancer Registrations in England, 2009. 
2
 I.e. among patients with one of the studied cancers who provided a valid answer to survey question 1, and with no missing 
data for ethnic group or deprivation. 
3
 1-year relative survival data are based on: Rachet B, Maringe C, Nur U, Quaresma M, Shah A, Woods LM, Ellis L, Walters 
S, Forman D, Steward J, Coleman MP. Population-based cancer survival trends in England and Wales up to 2007: an assess-
ment of the NHS cancer plan for England. Lancet Oncol. 2009;10(4):351-69.  
 
 45 
Figure Appendix 8-A.  Comparisons of incidence and sample proportions by cancer, against 1-year relative survival esti-
mates, men 
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Figure Appendix 8-B.  Comparisons of incidence and sample proportions by cancer, against 1-year relative survival es-
timates, women 
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Appendix 9 
Indirect comparison of unadjusted variation in number of general practitioner consultations before hospital referral 
observed in the Cancer Patient Experience Survey 2010 and the National Audit of Diagnosis of Cancer in Primary 
Care 
 
 
The proportion of patients who saw their general practitioner three or more times with cancer symptoms before hospital re-
ferral in the Cancer Patient Experience Survey 2010 (column 2) and in the National Audit of Cancer Diagnosis in Primary 
Care (column 4),
4
 is compared, by cancer: 
 
 
Table Appendix 9.  Comparison of proportions of patients with three or more pre-referral consultations in the Cancer 
Patient Survey 2010 and the National Audit of Cancer Diagnosis in Primary Care* 
 
Cancer 
Cancer Patient Experience Survey 2010 
(n=41,299) 
National Audit of Cancer Diagnosis in Prima-
ry Care (n=14,239) 
n N % Rank n N % Rank 
Multiple myeloma 939 1,854 50.6% 1 83 196 42.3% 1 
Pancreatic 193 467 41.3% 2 102 325 31.3% 4 
Brain 80 218 36.7% 3 39 167 23.4% 8 
Ovarian 504 1,390 36.3% 4 94 345 27.2% 6 
Stomach 269 748 36.0% 5 82 252 32.6% 2 
Lung 795 2,362 33.7% 6 494 1561 31.6% 3 
Lymphoma 1,132 3,376 33.5% 7 166 631 26.3% 7 
Cervical 86 287 30.0% 8 26 133 19.5% 13 
Renal 168 564 29.8% 9 67 295 22.8% 9 
Laryngeal 79 279 28.3% 10 23 107 21.5% 12 
Mesothelioma 77 275 28.0% 11 20 67 29.8% 5 
Colorectal 1,645 5,900 27.9% 12 467 2132 21.9% 11 
Leukaemia 465 1,686 27.6% 13 81 441 18.4% 14 
Vulval 46 171 26.9% 14 4 60 6.6% 19 
Oesophageal 274 1,099 24.9% 15 115 521 22.1% 10 
Thyroid 92 399 23.1% 16 11 99 11.2% 17 
Prostate 912 4,059 22.5% 17 376 2446 15.4% 15 
Bladder 931 5,209 17.9% 18 115 755 15.2% 16 
Endometrial 202 1,149 17.6% 19 36 371 9.7% 18 
Testicular 44 275 16.0% 20 8 139 5.7% 20 
Melanoma 113 1,124 10.1% 21 43 759 5.7% 21 
Breast 625 8,408 7.4% 22 76 2437 3.1% 22 
 
 
*Comparisons relate to 22 cancers because of aggregation in the audit report (which considered ‘colorectal’ and 
‘lymphoma’ as single categories including colon and rectal cancers, and Hodgkin’s and Non-Hodgkin lymphoma 
respectively). Data relating to patients diagnosed with cancer without prior general practitioner consultation with 
cancer symptoms, and missing data, were excluded from both datasets. 
 
 
There is a high degree of concordance in patterns of (unadjusted) variation by cancer site between the two da-
tasets: 
 
 The Spearman’s rank correlation coefficient is 0.899 (p<0·0001) – indicating high level of rank agreement. 
 
 Although the pattern of variation by cancer is similar, the proportion of patients with three or more pre-referral consulta-
tions is systematically (consistently) higher in the Cancer Patient Experience Survey 2010 compared to the audit dataset. This 
may reflect the fact that the Cancer Patient Experience Survey encompassed an unselected sample of patients (all patients 
treated in an NHS hospital during the first quarter of 2010); whereas the National Audit of Cancer Diagnosis in Primary Care 
                                                 
4
 http://www.rcgp.org.uk/pdf/National_Audit_of_Cancer_Diagnosis_in_Primary-Care.pdf  
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relates to patients registered with 1,170 general practices (a selected group of practices, representing 14% of all 8,387 prac-
tices in England). Other explanations include a systematic over-recall of this outcome when reported by cancer patients, or a 
systematic under-count in the audit dataset – e.g. because of incomplete capturing of symptoms in practice patient records. 
 
 Please also see Figure 7 in main paper – illustrating differences in proportions and 95% confidence intervals for the 15 
cancers with the largest sample size (excluding cancers with a sample size < 250 patients in the audit dataset). 
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Appendix 10 
Overview of cancer patient experience survey evidence – additional references 
 
The directly relevant publicly available report documents of the Cancer Patient Experience Survey 2010 and the National 
Audit of Diagnosis of Cancer in Primary Care are referenced in the main paper. We provide below a list of other papers, of 
indirect relevance to the study. 
 
1.  Patient-reported timeliness of cancer diagnosis 
 
 Neal RD, Allgar VL. Sociodemographic factors and delays in the diagnosis of six cancers: analysis of data from the 
"National Survey of NHS Patients: Cancer". Br J Cancer. 2005;92(11):1971-5. 
 
 Allgar VL, Neal RD. Delays in the diagnosis of six cancers: analysis of data from the National Survey of NHS Patients: 
Cancer. Br J Cancer. 2005;92(11):1959-70. 
  
2.  Cancer patient experience survey development or methodological considerations 
 
 Madden PB, Davies EA. Reporting cancer patients' experiences of care for quality improvement: analysis of 2000 and 
2004 survey results for South East England. J Eval Clin Pract. 2010;16(4):776-83. 
 
 Malin JL, Ko C, Ayanian JZ, Harrington D, Nerenz DR, Kahn KL, Ganther-Urmie J, Catalano PJ, Zaslavsky AM, Wal-
lace RB, Guadagnoli E, Arora NK, Roudier MD, Ganz PA. Understanding cancer patients' experience and outcomes: de-
velopment and pilot study of the Cancer Care Outcomes Research and Surveillance patient survey. Support Care Cancer. 
2006;14(8):837-48. 
 
3. Evaluation of care quality based on the experience of cancer patients 
 
 Davidson R, Mills ME. Cancer patients' satisfaction with communication, information and quality of care in a UK re-
gion. Eur J Cancer Care (Engl). 2005;14(1):83-90. 
 
 Sherlaw-Johnson C, Datta P, McCarthy M. Hospital differences in patient satisfaction with care for breast, colorectal, 
lung and prostate cancers. Eur J Cancer. 2008;44(11):1559-65.  
 
 McCarthy M, Datta P, Sherlaw-Johnson C, Coleman M, Rachet B. Is the performance of cancer services influenced 
more by hospital factors or by specialization? J Public Health (Oxf). 2008;30(1):69-74.  
 
 Ayanian JZ, Zaslavsky AM, Guadagnoli E, Fuchs CS, Yost KJ, Creech CM, Cress RD, O'Connor LC, West DW, 
Wright WE. Patients' perceptions of quality of care for colorectal cancer by race, ethnicity, and language. J Clin Oncol. 
2005;23(27):6576-86. 
 
 McCarthy M, Datta P, Sherlaw-Johnson C. Organizational determinants of patients' experiences of care for breast, lung 
and colorectal cancers. Eur J Cancer Care (Engl). 2009;18(3):287-94.  
 
 Allgar VL, Neal RD. General practitioners' management of cancer in England: secondary analysis of data from the Na-
tional Survey of NHS Patients-Cancer. Eur J Cancer Care (Engl). 2005;14(5):409-16. 
 
 
 
 
